122 Chapter 3 60. Stapleton NM, Einarsdottir HK, Stemerding AM, Vidarsson G. The multiple facets of FcRn in immunity. Immunol Rev. 2015;268: 253-268. 61. Zuercher AW, Spirig R, Baz Morelli A, Rowe T, Kasermann F. Next- generation fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366. 62. Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, ran- domised phase 2 trial. Lancet Neurol. 2018;17(6):519-529. 63. Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical effects of the self- administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled Multicenter Clinical Trial. JAMA Neurol. 2020;77(5):582-592. 64. Prevot J, Jolles S. Global immunoglobulin supply: steaming towards the iceberg? Curr Opin Allergy Clin Immunol. 2020;20(6): 557-564. 65. Kohn DB, Kuo CY. New frontiers in the therapy of primary immuno- deficiency: from gene addition to gene editing. J Allergy Clin Immunol. 2017;139(3):726-732. 66. Furlan JC, Barth D, Barnett C, Bril V. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve. 2016;53(6):872-876. 67. Grazzini G, Ceccarelli A, Calteri D, Catalano L, Calizzani G, Cicchetti A. Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing. Blood Transfus. 2013;11(Suppl 4):s138-s147. 68. Lanzoni M, Candura F, Calizzani G, Biffoli C, Grazzini G. Public expenditure for plasma-derived and recombinant medicinal products in Italy. Blood Transfus. 2013;11(Suppl 4):s110-s117. 69. Maheshwari A, Sharma RR, Prinja S, et al. Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre syndrome patients with therapeutic plasma exchange as compared to intrave- nous immunoglobulin. J Clin Apher. 2018;33(6):631637. 70. Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome. BMC Health Serv Res. 2011; 11:101. 71. Tsapepas D, Der-Nigoghossian C, Patel K, Berger K, Vawdrey DK, Salmasian H. Medication stewardship using computerized clinical decision support: a case study on intravenous immunoglobulins. Pharmacol Res Perspect. 2019;7(5):e00508. 72. Derman BA, Schlei Z, Parsad S, Mullane K, Knoebel RW. Changes in intravenous immunoglobulin usage for Hypogammaglobulinemia after implementation of a stewardship program. JCO Oncol Pract. 2021;17(3):e445-e453. 73. Sanders DB, Wolfe GI, Narayanaswami P. Developing treatment guidelines for myasthenia gravis. Ann N Y Acad Sci. 2018;1412(1): 95-101.
RkJQdWJsaXNoZXIy MTk4NDMw